Press News

Press News

2012.08.21 New Region Added for Exclusive Rights for WT1 Peptides Patent and Expiration Date Extended

tella, Inc. (Head office: Chiyoda-ku, Tokyo; President & Representative Director: Yuichiro Yazaki) has signed an agreement with Cancer Immunity Research Institute Co., Ltd. (Head office: Suita City, Osaka; President: Junichi Terai) to revise the contract for exclusive patent licensing rights for the WT1 peptides patent held by Cancer Immunity Research Institute. Currently, tella has the exclusive right to use the WT1 peptides patent in Japan and China. This agreement will allow tella to start using the patent in other countries in Asia, including Indonesia, Malaysia, Singapore and other ASEAN nations. Economic growth is strong in this region and demand for advanced cancer treatments is expected to continue to increase. tella will have the exclusive right to supply technologies and know-how in this region concerning the WT1 peptide pulsed DC vaccine therapy and other therapies. In addition, expiration of the exclusive right to use the patent has been extended from the current December 31, 2016 to the expiration date of the patent.
WT1 peptides are a type of protein called WT1 (Wilms’ tumor gene 1) that were discovered by Professor Haruo Sugiyama of Osaka University and others. These peptides are one of the world’s best-known cancer antigens (the characteristics of the cancer). WT1 is found in almost all types of cancer (including blood cancer). Using this substance makes it possible to provide the DC vaccine therapy to an even larger number of cancer patients. Based on this agreement, tella will accelerate the pace of activities to increase the use of the WT1 peptide pulsed DC vaccine therapy and other therapies in Asia, primarily in the ASEAN region and China. This agreement will have only a negligible effect on results of operations in fiscal 2012.

 

TopPage